Skip to main content

Table 1 Patient characteristics and outcomes

From: Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda

Patient characteristics Cohort M12
(N = 229)
Cohort M24
(N = 277)
Characteristics at ART start   
   Women (%) 151 (65.9) 173 (62.4)
   Median age, years [IQR] 36.8 [32.0–42.3] 36.5 [30.8–42.6]
   ARV naïve (%)* 225 (98.2) 273 (98.6)
   Median follow-up before ART, months [IQR] 6.2 [3.9–11.4] 3.7 [1.8–7.7]
   First ART regimen prescribed d4T/3TC/NVP 226 (98.7) 265 (95.7)
   WHO stage 3 or 4 (%) 201 (87.7) 246 (88.8)
   Body mass index <17 kg/m2 (%) 38 (17.8); n = 214 43 (16.8); n = 256
   CD4 cell count, cells/mm3 n = 133 n = 239
Median [IQR] 100 [45–147] 93 [40–144]
<50 (%) 36 (27.1) 73 (30.5)
Characteristics at time of survey   
   Non-cumulative WHO stage at survey (%) n = 223 n = 267
Asymptomatic 136 (61.0) 160 (59.9)
Stage 1 or 2 63 (28.2) 86 (32.2)
Stage 3 or 4 24 (10.8) 21 (7.9)
   Body mass index, kg/m2   
Median [IQR] 20.4 [18.9–22.0] 20.8 [19.0–22.5]
<18.5 kg/m2 (%) 43 (18.8) 52 (18.7)
   Median weight gain since ART start, kg [IQR] 3 [1–6] 2 [0–7]
   ARV-clinical related symptoms (%)   
Asthenia 70 (30.7) 84 (30.3)
Digestive disorders 132 (57.6) 146 (52.7)
Neurological disorders 102 (44.5) 111 (40.1)
Dermatological disorders 70 (30.6) 84 (30.3)
Morphological disorders 39 (17.0) 72 (26.0)
   CD4 cell count, cells/mm3   
Median [IQR] 223 [163–308] 238 [172–321]
<200 (%) 92 (40.2) 100 (36.1)
Median gain since ART start [IQR] +115 [59–170] +139 [75–215]
   Pills taken in last 4 days (%)   
Good adherence 200 (87.3) 258 (93.1)
Poor adherence 29 (12.6) 19 (6.9)
   30-day VAS (%)   
Good adherence 198 (86.5) 250 (90.3)
Poor adherence 31 (13.5) 27 (9.7)
   Plasmatic NVP level (%) n = 204 n = 258
Low 39 (19.1) 32 (12.4)
Normal 115 (56.4) 172 (66.7)
High 50 (24.5) 54 (20.9)
   Plasmatic EFV level (%) n = 23 n = 18
Low 1 (4.4) -
Normal 13 (56.5) 11 (61.1)
High 9 (39.1) 7 (38.9)
  1. VAS, visual analogue scale; IQR, interquartile range
  2. *ARV-naïve does not include women who received PMTCT prophylaxis.